AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04982692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravaginal prasterone
Description: 6.5 mg of Intravaginal prasterone once daily at bedtime with a finger to insert the vaginal suppository into the vagina for a treatment cycle of 12 weeks.
Study NCT04982692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ovules
Description: Placebo ovules once daily at bedtime with a finger to insert the vaginal suppository into the vagina for a treatment cycle of 12 weeks.
Study NCT05482321 — intervention group
Intervention type: DRUG
Intervention: Definity Suspension for Injection
Description: * DEFINITY is administered as per manufactures instructions~* 1 vial of DEFINITY is allowed to warm to room temperature and activated by 45s shaking on a VIALMIX~* Withdraw the activated milky white suspension using the provided Dispensing Pin, PINSYNC or 18-20 gauge syringe needle, from the middle of the liquid in the inverted vial.~* Deliver a dose of 10 μl/kg of 'milky white suspension' IV as a bolus, delivered over 30seconds.~* Following imaging, provide a 10 mL flush of preservative-free saline~* Wait at least 30minutes until second dose (if provided).
Study NCT05846399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin/clavulanate
Description: Amoxicillin-clavulanate 875-125mg by mouth twice daily for 1 day or Ciprofloxacin 500mg by mouth twice daily and clindamycin 450mg by mouth twice daily for 1 day
Study NCT05846399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Amoxicillin-clavulanate 875-125mg by mouth twice daily for 5 days or Ciprofloxacin 500mg by mouth twice daily and clindamycin 450mg by mouth twice daily for 5 days
Study NCT05846399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: Amoxicillin-clavulanate 875-125mg by mouth twice daily for 5 days or Ciprofloxacin 500mg by mouth twice daily and clindamycin 450mg by mouth twice daily for 5 days
Study NCT05846399 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (microcrystalline cellulose)
Description: Placebo (microcrystalline cellulose) by mouth twice daily by mouth for 5 days
Study NCT05846399 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (microcrystalline cellulose)
Description: Placebo (microcrystalline cellulose) by mouth twice daily by mouth for 5 days
Study NCT05846399 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound management
Description: Wound management includes hemostasis, copious irrigation, removal of foreign bodies, and excisional debridement of devitalized tissue. If only punctures are present, lancing of the punctures is not typically required unless infection has already developed. Local anesthesia (1% lidocaine hydrogen chloride (HCl) with epinephrine 1:100,000; 200mg/20mL vial) will be used prior to irrigation (30mL of povidone-iodine in 1L of 0.9% sodium chloride (NaCl) solution and/or 118mL of 3% hydrogen peroxide) and debridement. Open wounds will be irrigated and debrided at bedside. Wounds will be covered with soft dressings in place until first follow-up at day 2.
Study NCT05846399 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Wound management
Description: Wound management includes hemostasis, copious irrigation, removal of foreign bodies, and excisional debridement of devitalized tissue. If only punctures are present, lancing of the punctures is not typically required unless infection has already developed. Local anesthesia (1% lidocaine hydrogen chloride (HCl) with epinephrine 1:100,000; 200mg/20mL vial) will be used prior to irrigation (30mL of povidone-iodine in 1L of 0.9% sodium chloride (NaCl) solution and/or 118mL of 3% hydrogen peroxide) and debridement. Open wounds will be irrigated and debrided at bedside. Wounds will be covered with soft dressings in place until first follow-up at day 2.
Study NCT06649136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: comparison between oral and subcutaneous methotrexate dosis of 25mg
Study NCT06647706 — intervention group
Intervention type: DEVICE
Intervention: Transthoracic echocardiography
Description: MPNs patients who have echocardiographic probability of PH
Study NCT05780970 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Non-treated children and caregivers complete assessments only. The primary (treated) parent / adolescent dyad participate in family based weight management treatment through the main trial. In the main trial, families are randomized to either TEENS+Parents as Coaches (parent skills training) or TEENS+Parent Weight Loss (parent behavioral weight loss).
Study NCT06275711 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic communication methods
Description: Drawing pictures, story completion, breathing and relaxation exercises
Study NCT05874375 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Urge stimulation
Description: Participants will receive stimulation for 60 seconds, when they feel an urgency.
Study NCT05874375 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Time limited stimulation
Description: Participant will receive the stimulation as provided in time limited sessions (Range: 15 min - continuous), whenever it suits the participant during the day.
Study NCT05116202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab will be administered at a dose of 3 mg/kg IV on Day 1 of each 21 day cycle.
Study NCT05116202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Ipilimumab will be administered at a dose of 1 mg/kg by IV on Day 1 of each 21 day cycle.
Study NCT05116202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7247669 2100 mg
Description: RO7247669 will be administered at a dose of 2100 mg by IV infusion on Day 1 of each 21 day cycle.
Study NCT05116202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a dose of 1200 mg IV on Day 1 of each 21 day cycle.
Study NCT05116202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab will be administered at a dose of 600 mg IV on Day 1 of each 21 day cycle.
Study NCT05116202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7247669 600 mg
Description: RO7247669 will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.
Study NCT03716843 — intervention group
Intervention type: OTHER
Intervention: Pressure monitoring system
Description: The pressure measurement undergarment will be given to all consenting AIS patients who have received their own thoraco-lumbo-sacral orthosis (TLSO) rigid brace. Each patient will wear the undergarment first and the TLSO brace on top. FBG sensors embedded in the undergarment will measure each pressure signal at approximately 2 minutes. The average force reading will be calculated.~Then, the experiment will be repeated once, but the anisotropic textile brace will replace the TLSO brace. The pressure measurement system will be used to obtain an accurate and adequate comparison of the forces applied to the patients. The effectiveness of the anisotropic textile brace will be evaluated through X-ray radiography, and its correction effect with be compared with that of the TLSO brace.
Study NCT06408220 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy
Study NCT06408220 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06408220 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breath Test
Description: Undergo H. pylori breath test
Study NCT06408220 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagogastroduodenoscopy
Description: Undergo EGD
Study NCT06408220 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagogastroduodenoscopy
Description: Undergo EGD
Study NCT06408220 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT06408220 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT04946032 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Epidural catheter
Description: The epidural catheter length will vary, either 4 cm or 5 cm into the epidural space.
Study NCT05205343 — intervention group
Intervention type: OTHER
Intervention: Standard of Care
Description: complete a questionnaire within 30 days before your surgery and then at 1, 3, 6, and 12 months after surgery
Study NCT05205343 — intervention group
Intervention type: OTHER
Intervention: Control Group
Description: complete a questionnaire within 30 days before your surgery and then at 1, 3, 6, and 12 months after surgery
Study NCT05856539 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane (ESP) block
Description: ESP block is an opioid-sparing regional anesthetic involving bupivacaine and dexamethasone for lumbar spinal surgery with touted benefits including opioid use reduction and improved pain control.
Study NCT06207149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASISTIR
Description: This will be a 24 hour advocacy program focused on adult disability services.
Study NCT06207149 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ASISTIR
Description: This will be a 24 hour advocacy program focused on adult disability services.
Study NCT05000203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online prenatal specific education
Description: The sessions will start around 30 weeks of gestation with the intention that around 35-37 weeks all pregnant women have had the opportunity to attend all the sessions.~Five specific online group sessions have been established for the fear of childbirth, each divided into three parts, and lasting approximately 60 minutes. In the first part, the aspects that are most relevant according to the reported experience of women with fear of childbirth will be discuss. In a second part, videos will be displayed starring midwives who will collaborate in specific intrapartum support with the aim of presenting the personnel involved in the care of women during delivery and immediate postpartum, and where the procedures and options available in the obstetric service of HUMIC. The session will end with brief therapy tasks. After each session, written documentation on the topics discussed will be made available to the participants.
Study NCT05000203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intrapartum specific support
Description: At first, a group of expert midwives will be formed in support of pregnant women with fear of childbirth. The objective is that three midwives from each work group shift will include the women from the experimental group in the intrapartum support team. The working group will receive a seminar given by the researcher where the study protocol and an update on fear of childbirth will be explained, which will include information on: concept and prevalence, risk factors, consequences, diagnosis and treatment.~For the follow-up of the participants, an instant messaging group will be formed where the collaborating midwives and the main researcher will be able to find out the existence of a participant within the emergency area or in the maternity ward, facilitating continued care in the changes of guard
Study NCT05000203 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prenatal usual education
Description: The participants in this group will follow the development of the usual interventions by midwives and obstetricians according to the established protocol for monitoring the pregnancy and / or by the private care system, as well as additional consultations for complications in pregnancy or consultations on demand that are considered necessary Group maternal education is offered in primary care center starting at week 28 of gestation. Although its content is supported by the Affective-Sexual and Reproductive Health Care Program, midwives are responsible for preparing the sessions according to their criteria to adapt them to the population. In addition to group interventions, pregnant women in the intervention environment also receive individualized educational attention in follow-up and control visits. After delivery, an inquiry will be made about the maternal education received by pregnant women during their current pregnancy.
Study NCT05000203 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intrapartum usual support
Description: A routine detection of fear of childbirth or a protocolized practice for this problem is currently not contemplated in the trial setting. The different professionals who pay their attention to the pregnant woman can detect the fear of childbirth thanks to their experience or different indicators such as the expression of fears by the pregnant woman, being able to offer individualized attention and resources for the approach, according to their awareness of the problem .
Study NCT04015791 — intervention group
Intervention type: OTHER
Intervention: NOCISCAN-LS Disc MR Spectroscopy
Description: The investigational Nociscan Suite is a software suite that works with existing high field MR systems and MRS pulse sequence via and optimized protocol to conduct MRS exam of lumbar discs. The software suite post-processes the NOCISCAN-LS disc MRS exam data to calculate ratios of spectroscopic signals at regions along the MRS frequency spectrum associated with certain chemicals that change with degeneration and pain
Study NCT06647563 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Specified dose on specified days
Study NCT06647563 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Specified dose on specified days
Study NCT06647563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: Specified dose on specified days
Study NCT06647563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Specified dose on specified days
Study NCT06647563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Specified dose on specified days
Study NCT06647563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Specified dose on specified days
Study NCT06647563 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy 60 Gray/day
Description: Low risk participants administered 2 Gray/day in 30 fractions. Administered using intensity modulated radiation therapy.
Study NCT06647563 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy 60 Gray/day
Description: Low risk participants administered 2 Gray/day in 30 fractions. Administered using intensity modulated radiation therapy.
Study NCT06647563 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy 66 Gray/day
Description: High risk participants administered 2 Gray/day in 33 fractions. Administered using intensity modulated radiation therapy.
Study NCT06647563 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy 66 Gray/day
Description: High risk participants administered 2 Gray/day in 33 fractions. Administered using intensity modulated radiation therapy.
Study NCT06647563 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy 70 Gray/day
Description: Participants with gross residual disease administered 2 Gray/day in 35 fractions. Administered using intensity modulated radiation therapy.
Study NCT06647563 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy 70 Gray/day
Description: Participants with gross residual disease administered 2 Gray/day in 35 fractions. Administered using intensity modulated radiation therapy.
Study NCT05496283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: denture adhesive
Description: After 1 month of using the complete denture with no denture adhesives, patients fill up satisfaction and quality of life forms and given 1 of 3 types of denture adhesive to use for month to compare satisfaction and quality of life forms
Study NCT06315478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole 20 MG Oral Tablet
Description: standard triple therapy for 14 days Bid for each drug
Study NCT06315478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin 500Mg Tab
Description: Quadruple regimen for 14 days Bid for each drug
Study NCT06315478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin 500Mg Tab
Description: Hybrid regimen, PPI and Amoxicillin for first 7 days then adding clarithromycin and metronidazole for the second 7 days
Study NCT05212701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reparixin
Description: The oral tablets of the investigational product (IP) will be administered with water prior to the start of the anticancer treatment infusion on Day 1 Cycle 1 and then administered approximately every eight hours (± 2 h) with a glass of water (about 250 mL) and a light meal or snack (it is preferable that reparixin is taken with food).
Study NCT05212701 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The oral tablets of masked placebo will be administered with water prior to the start of the anticancer treatment infusion on Day 1 Cycle 1 and then administered approximately every eight hours (± 2 h) with a glass of water (about 250 mL) and a light meal or snack
Study NCT05847257 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Letrozole tablets
Description: letrozole 2.5mg twice weekly for 3 months
Study NCT05847257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole tablets
Description: letrozole 2.5mg twice weekly for 3 months
Study NCT05847257 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 table
Description: Coenzyme Q10 400 mg per day for 3 months
Study NCT06333574 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Family weight self-measurement and remote follow-up management based on wechat.
Description: On the basis of routine outpatient management, patients or their family members were subjected to remote follow-up management based on wechat, and the follow-up time was 6 months. Specific methods: Same as the control group, the information of weight and blood pressure of the patients was registered at the end of dialysis, and the purpose, role and importance of weight management were informed to the patients. On this basis, a special wechat signal is set up to add patients or patients' family members as wechat friends and establish a wechat interaction platform with patients. In the interdialysis period, remind patients to weigh themselves through wechat (the time of each weighing is fixed, preferably consistent with the time of weighing in the hemodialysis center), control the weight gain during the interdialysis period not to exceed 4.5% of dry weight, and inform patients again about the purpose, role and importance of weight management.
Study NCT06333574 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine care
Description: The dialysis doctor registered the information of the patient's weight and blood pressure at the end of dialysis, and informed the patient of the purpose, role and importance of weight management.
Study NCT04711603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR13A9
Description: Intravenous administration
Study NCT04711603 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MR13A9
Description: Intravenous administration
Study NCT04711603 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous administration
Study NCT06426862 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Otago Exercise Program
Description: Otago exercise program~Strengthening Exercise Knee extensor, Hip adductors, heel and toe raising~Balance exercise Sit to stand, Knee bending, one leg standing, tandem stance, side walk, walk and turn around, tandem walk, backward walk, heel and toe walk, stair climbing
Study NCT06426862 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Routine physiotherapy like strengthening, stretching, postural awareness, gait and balance training.
Study NCT06426862 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: Routine physiotherapy like strengthening, stretching, postural awareness, gait and balance training.
Study NCT05148234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Decitabine
Description: For Higher Risk (HR) Myelodysplastic Syndromes (MDS) cohort, the study drug of BMS-986253 will be given in combination with standard of care (SOC) Food and Drug Administration (FDA)-approved DNMTi by mouth (PO) decitabine and cedazuridine according to guidelines outlined in FDA product label. Standard of care (SOC) DNMTi will be administered via oral route once daily starting Day (D)2 of each treatment cycle through D6.
Study NCT05148234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Cedazuridine
Description: For Higher Risk (HR) Myelodysplastic Syndromes (MDS) cohort, the study drug of BMS-986253 will be given in combination with standard of care (SOC) Food and Drug Administration (FDA)-approved DNMTi by mouth (PO) decitabine and cedazuridine according to guidelines outlined in FDA product label. Standard of care (SOC) DNMTi will be administered via oral route once daily starting Day (D)2 of each treatment cycle through D6.
Study NCT05148234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986253
Description: Intravenous (IV) infusion, 200 mg/Vial (20 mg/mL) or 1000 mg/vial (100mg/mL). Abbreviated Title: Human Humax (HuMax)-interleukin 8 (IL-8) (BMS-986253) in Myelodysplastic Syndromes 34 Version Date: 9/08/2021 outlined in Food and Drug Administration (FDA) product label.